Trial Profile
Single-dose Pilot Study of Oral Rivaroxaban in Pediatric Subjects With Venous Thromboembolism
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Bayer
- 05 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 30 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 03 Jun 2015 Planned End Date changed from 1 Jun 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov record.